Nestorone Microarray Patch
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Intradermal
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Queens University Belfast, Population Council
Details
- API: Nestorone
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Poly (Vinyl Alcohol) and Poly (Vinyl Pyrrolidone)
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: MAPs in general have a number of well-documented potential advantages - ease of use, potential for affordability, desirable max duration, shelf stable.
Product Status
Recent Pre-Clinical Research. Product no longer appears on Population Council product pipeline report - record will be monitored for updates.
History
2022: Researchers representing Queen's University Belfast and Istanbul University publish pre-clinical results indicating the potential viability of a NES-nanosuspension-loaded bilayer dissolving microneedle array as a contraceptive method.